In a recent address from the White House on December 17th, Donald Trump reflected on his actions and impact during the first year of his second term in office. During the 18-minute speech, the President covered a wide array of topics he focused on over the past 12 months, including wages, job creation, military strength, and efforts to address illegal immigration.
Trump also emphasized his successful negotiations with major pharmaceutical companies such as Pfizer and AstraZeneca to lower the prices of certain medications in the US to levels comparable to those in other countries, aiming to provide cost savings for millions of Americans.
However, some observers pointed out a potential error in Trump’s statement regarding reducing drug prices by up to 600%. Mathematically, a price reduction beyond 100% would imply pharmaceutical companies paying consumers to use their products, which is not feasible.
While Trump has engaged in talks with various pharmaceutical companies to secure deals, it remains uncertain whether these agreements have directly benefited consumers. Reports indicate that the specific terms of the deals are confidential or still under negotiation.
Critics seized the opportunity to comment on Trump’s mathematical oversight, questioning the feasibility of a 600% price reduction and highlighting the importance of basic math knowledge. Despite varying opinions on Trump’s delivery and intentions, some suggest his aim is to eliminate excessive markups on drugs, potentially bringing prices closer to production costs.
The discourse following Trump’s speech showcased a range of reactions, with some likening his presentation style to late-night infomercials and others dissecting the implications of his statements.